Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To evaluate efficacy of the dual therapy of atorvastatin + amlodipine vs. amlodipine alone .
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| atorvastatin | Drug | |||
| amlodipine | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate efficacy of the dual therapy of atorvastatin 10mg or 20mg + amlodipine 5mg or 10mg vs. amlodipine 5mg or 10mg alone |
| Measure | Description | Time Frame |
|---|---|---|
| To provide comparative evaluation of the safety profile of the dual therapy with atorvastatin + amlodipine versus amlodipine alone. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Beijing | Beijing Municipality | 100044 | China | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Guangzhou |
| Guangdong |
| 510080 |
| China |
| Pfizer Investigational Site | Guangzhou | Guangdong | 510100 | China |
| Pfizer Investigational Site | Guangzhou | Guangdong | 510515 | China |
| Pfizer Investigational Site | Nanjing | Jiangsu | 210029 | China |
| Pfizer Investigational Site | Shenyang | Liaoning | 110016 | China |
| Pfizer Investigational Site | Shanghai | Shanghai Municipality | 200032 | China |
| Pfizer Investigational Site | Hangzhou | Zhejiang | 310016 | China |
| Pfizer Investigational Site | Beijing | 100029 | China |
| Pfizer Investigational Site | Beijing | 100083 | China |
| Pfizer Investigational Site | Beijing | China |
| Pfizer Investigational Site | Shanghai | 200003 | China |
| Pfizer Investigational Site | Shanghai | 200025 | China |
| Pfizer Investigational Site | Shanghai | 200233 | China |
| Pfizer Investigational Site | Tianjin | 300211 | China |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| D017311 | Amlodipine |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D004095 | Dihydropyridines |
| D011725 | Pyridines |
Not provided
Not provided